Date:8/10/2009

---- ---- (unaudited) ASSETS Current assets: Cash and cash equivalents $4,397 $3,270 Short-term investments 1,006 10,292 Receivables 44 126 Prepaid expenses and other current assets 472 805 --- --- Total current assets 5,919 14,493 Property and equipment, net 6,601 6,938 Other assets and patent pending, net 1,334 1,073 ----- ----- Total assets $13,854 $22,504 ======= ======= LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $408 $521 Accrued clinical and costs of other studies 60 73 Accrued compensation and benefits 443 456 Current portion of lease obligations 638 682 Current portion of notes payable 7 - Other current liabilities 717 595 --- --- Total current liabilities 2,273 2,327 Non-current portion of lease obligation 260 545 Non-current portion of notes payable 92 - --- --- Total l
'/>"/>

SOURCE Bionovo, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings